Table 5.
The relationship between mGPS, clinicopathological characteristic, and systemic inflammation in patients undergoing elective surgery for colorectal cancer (n = 650)
| Characteristic | mGPS 0 | mGPS 1 and 2 (n = 151) | P‐value | |
|---|---|---|---|---|
| Clinicopathological | ||||
| Age | ≤65 | 185 (37.1) | 49 (32.5) | 0.410 |
| 65–74 | 193 (38.7) | 58 (38.4) | ||
| >74 | 121 (24.2) | 44 (29.1) | ||
| Sex | Female | 228 (45.7) | 68 (45.0) | 0.887 |
| Male | 271 (54.3) | 83 (55.0) | ||
| ASA score | 1 | 120 (24.0) | 21 (13.9) | 0.036 |
| 2 | 221 (44.3) | 76 (50.3) | ||
| 3 | 146 (29.3) | 47 (31.1) | ||
| 4 | 12 (2.4) | 7 (4.6) | ||
| Laparoscopic surgery | No | 303 (60.7) | 104 (68.9) | 0.070 |
| Yes | 196 (39.3) | 47 (31.1) | ||
| TNM | 0 | 13 (2.6) | 1 (0.7) | <0.001 |
| I | 135 (27.1) | 20 (13.2) | ||
| II | 173 (34.7) | 90 (59.6) | ||
| III | 178 (35.7) | 40 (26.5) | ||
| Venous invasion | No | 199 (39.9) | 67 (44.4) | 0.325 |
| Yes | 300 (60.1) | 84 (55.6) | ||
| Tumour location | Right and transverse | 175 (35.1) | 72 (47.7) | 0.014 |
| Left | 112 (22.4) | 33 (21.9) | ||
| Rectum | 197 (39.5) | 40 (26.5) | ||
| Total and subtotal | 15 (3.0) | 6 (4.0) | ||
| Adjuvant chemotherapy | No | 293 (66.9) | 92 (68.7) | 0.704 |
| Yes | 206 (33.1) | 59 (31.3) | ||
| Systemic inflammation | ||||
| NLR | ≤3 | 308 (61.7) | 61 (40.4) | <0.001 |
| >3 | 191 (38.3) | 90 (59.6) | ||
| NPS | 0 | 459 (92.0) | 109 (72.2) | <0.001 |
| 1 | 38 (7.6) | 29 (19.2) | ||
| 2 | 2 (0.4) | 13 (8.6) | ||
| Body composition | ||||
| BMI (kg/m2) | <25 | 156 (31.3) | 63 (41.7) | 0.017 |
| ≥25 | 343 (68.7) | 88 (58.3) | ||
| High SFI | No | 84 (16.8) | 32 (21.2) | 0.220 |
| Yes | 415 (83.2) | 119 (78.8) | ||
| Visceral obesity | No | 129 (25.9) | 48 (31.8) | 0.151 |
| Yes | 370 (74.1) | 103 (68.2) | ||
| Low SMI (sarcopenia) | ||||
| SMI (Martin) | No | 298 (59.7) | 69 (45.7) | 0.002 |
| Yes | 201 (40.3) | 82 (54.3) | ||
| SMI (Dolan BMI ≥ 25) | No | 299 (59.9) | 72 (47.7) | 0.008 |
| Yes | 200 (40.1) | 79 (52.3) | ||
| SMI (Caan) | No | 254 (50.9) | 59 (39.1) | 0.011 |
| Yes | 245 (49.1) | 92 (60.9) | ||
| SMI (Dolan BMI ≥ 30) | No | 309 (61.9) | 77 (51.0) | 0.017 |
| Yes | 190 (38.1) | 74 (49.0) | ||
| Low SMD (myosteatosis) | ||||
| SMD (Martin) | No | 214 (42.9) | 44 (29.1) | 0.002 |
| Yes | 285(57.1) | 107 (70.9) | ||
| SMD (Dolan BMI ≥ 25) | No | 274 (54.9) | 69 (45.7) | 0.047 |
| Yes | 225 (45.1) | 82 (54.3) | ||
| SMD (Xiao) | No | 242 (48.5) | 67 (44.4) | 0.374 |
| Yes | 257 (51.5) | 84 (55.6) | ||
| SMD (Dolan Male/Female) | No | 241 (48.3) | 63 (41.7) | 0.156 |
| Yes | 258 (51.7) | 88 (58.3) | ||
BMI, body mass index; mGPS, modified Glasgow prognostic score; NLR, neutrophil lymphocyte ratio; NPS, neutrophil‐platelet score; SFI, subcutaneous fat index; SMD, skeletal muscle density; SMI, skeletal muscle index.